{"protocolSection": {"identificationModule": {"nctId": "NCT00374907", "orgStudyIdInfo": {"id": "CV181-041"}, "organization": {"fullName": "AstraZeneca", "class": "INDUSTRY"}, "briefTitle": "A Study Assessing Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise", "officialTitle": "Mechanism of Action and Efficacy of Saxagliptin (BMS-477118) in the Treatment of Type 2 Diabetic Patients"}, "statusModule": {"statusVerifiedDate": "2015-03", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2006-09"}, "primaryCompletionDateStruct": {"date": "2008-01", "type": "ACTUAL"}, "completionDateStruct": {"date": "2009-12", "type": "ACTUAL"}, "studyFirstSubmitDate": "2006-09-07", "studyFirstSubmitQcDate": "2006-09-11", "studyFirstPostDateStruct": {"date": "2006-09-12", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2010-12-26", "resultsFirstSubmitQcDate": "2010-12-26", "resultsFirstPostDateStruct": {"date": "2011-01-21", "type": "ESTIMATED"}, "dispFirstSubmitDate": "2009-07-30", "dispFirstSubmitQcDate": "2010-08-13", "dispFirstPostDateStruct": {"date": "2010-08-18", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2015-04-20", "lastUpdatePostDateStruct": {"date": "2015-05-07", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "AstraZeneca", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "The purpose of this clinical research study is to learn whether Saxagliptin can improve the body's ability to make its own insulin and lower blood sugar in people with type 2 diabetes", "detailedDescription": "All subjects will participate in a lead-in period, and qualifying subjects will continue into a short-term randomized treatment period. Subjects who complete the short-term period will be eligible to enter the long term extension period. Also, subjects who have an elevated blood sugar that requires additional medication for blood sugar control will be eligible to receive open-label metformin added onto their blinded study medication"}, "conditionsModule": {"conditions": ["Type 2 Diabetes"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 156, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Saxagliptin (A)", "type": "EXPERIMENTAL", "description": "Metformin 500-1500 mg (open-label, as needed for rescue in LT)", "interventionNames": ["Drug: Saxagliptin"]}, {"label": "Placebo (ST) / Metformin (LT) (B)", "type": "PLACEBO_COMPARATOR", "description": "Metformin 500-1500 mg (open-label, as needed for rescue in LT)", "interventionNames": ["Drug: Placebo", "Drug: Metformin (blinded)", "Drug: Metformin (open-label)"]}], "interventions": [{"type": "DRUG", "name": "Saxagliptin", "description": "Tablet, Oral, 5 mg, Once daily, (up to 12 weeks ST, up to 104 weeks LT)", "armGroupLabels": ["Saxagliptin (A)"], "otherNames": ["BMS-477118"]}, {"type": "DRUG", "name": "Placebo", "description": "Tablet, Oral, 0 mg, Once daily (up to 12 weeks ST)", "armGroupLabels": ["Placebo (ST) / Metformin (LT) (B)"]}, {"type": "DRUG", "name": "Metformin (blinded)", "description": "Tablet, Oral, 500 mg titrated to 1000 mg, Once daily (up to 104 weeks LT, starting at Week 12)", "armGroupLabels": ["Placebo (ST) / Metformin (LT) (B)"]}, {"type": "DRUG", "name": "Metformin (open-label)", "description": "Tablets, Oral, 500-1500 mg, as needed (starting in LT)", "armGroupLabels": ["Placebo (ST) / Metformin (LT) (B)"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Insulin Secretion Rate Area Under the Curve (AUC) During Intravenous (IV)-Oral Hyperglycemic Clamp - Percent Change From Baseline at Week 12", "description": "Adjusted percent change in the insulin secretion rate AUC during a hyperglycemic clamp with an enteral glucose load \\[intravenous-oral hyperglycemic clamp (180-480 minutes)\\] at Week 12. The method used for calculating the insulin secretion rate was C-peptide deconvolution.", "timeFrame": "Baseline, Week 12"}], "secondaryOutcomes": [{"measure": "Insulin Secretion Rate AUC During IV Hyperglycemic Clamp - Percent Change From Baseline at Week 12", "description": "Adjusted percent change in the insulin secretion rate AUC during an intravenous hyperglycemic clamp (120-180 minutes) at Week 12. The method used for calculating the insulin secretion rate was C-peptide deconvolution.", "timeFrame": "Baseline, Week 12"}], "otherOutcomes": [{"measure": "Overall Summary of Adverse Events (AEs) Serious AEs (SAEs), Discontinuations, and Deaths During the ST + LT Treatment Period", "description": "AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event. Related events=relationship of certain, probable, possible, or missing.", "timeFrame": "116 weeks"}, {"measure": "Marked Laboratory Abnormalities - During ST + LT Treatment Period", "description": "A laboratory value was considered a marked abnormality if it is outside the pre-defined criteria for marked abnormality and the on-treatment value was more extreme (farther from the limit) than the baseline value. Pre-Rx=pretreatment; ULN=upper limit of normal; ALP=alkaline phosphatase; AST=aspartate aminotransferase; ALT=alanine aminotransferase; BUN=blood urea nitrogen; unspec.=unspecified; sodium serum low: \\<0.9 x Pre-Rx \\& \\<=130mEq/L / high: \\>1.1 x Pre-Rx \\& \\>=150mEq/L; potassium, serum low: \\<=0.8 x Pre-Rx \\& \\>=6.0mEq/L / high: 1.2 x Pre-Rx \\& \\>=6.0mEq/L; LLN=lower limit of normal.", "timeFrame": "116 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Type 2 diabetes mellitus\n* Drug naive\n* Hemoglobin A1c (HbA1c) \u22656.0% and \u22648.0%\n* Fasting C-peptide \u22651.0 ng/mL\n* Body mass index \u226440 kg/m\u00b2\n\nExclusion Criteria:\n\n* Recent cardiac or cerebrovascular event\n* Elevated serum creatinine", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "70 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Bristol-Myers Squibb", "affiliation": "Bristol-Myers Squibb", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Va San Diego Healthcare System", "city": "San Diego", "state": "California", "zip": "92161", "country": "United States", "geoPoint": {"lat": 32.71533, "lon": -117.15726}}, {"facility": "Pennington Biomedical Research Center", "city": "Baton Rouge", "state": "Louisiana", "zip": "70808", "country": "United States", "geoPoint": {"lat": 30.45075, "lon": -91.15455}}, {"facility": "Diabetes & Glandular Disease Research Assoc,, Inc.", "city": "San Antonio", "state": "Texas", "zip": "78229", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "156 participants were enrolled in the study; 110 participants failed screening; 10 subjects entered lead-in and discontinued prior to randomization.", "groups": [{"id": "FG000", "title": "Saxagliptin 5 mg", "description": "Tablet, Oral, 5 mg, once daily, up to 12 weeks (short-term) and up to 104 weeks (long-term). Metformin 500-1500 mg (open-label, as needed for rescue in LT)."}, {"id": "FG001", "title": "Placebo / Metformin", "description": "Placebo Tablet, Oral, 0 mg, once daily, up to 12 weeks; Metformin Tablet, Oral, 500 mg/1000 mg, once daily, up to 104 weeks starting at Week 12 (end of ST period). Metformin 500-1500 mg (open-label, as needed for rescue in LT)."}], "periods": [{"title": "12-Week Short-term Period", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "20"}, {"groupId": "FG001", "numSubjects": "16"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "17"}, {"groupId": "FG001", "numSubjects": "15"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "1"}]}], "dropWithdraws": [{"type": "Subject Withdrew Consent", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "1"}]}]}, {"title": "116-Week Short-term + Long-term Period", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "20"}, {"groupId": "FG001", "numSubjects": "16"}]}, {"type": "Completed 12-week Short Term Period", "achievements": [{"groupId": "FG000", "numSubjects": "17"}, {"groupId": "FG001", "numSubjects": "15"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "13"}, {"groupId": "FG001", "numSubjects": "14"}]}], "dropWithdraws": [{"type": "Subject Withdrew Consent", "reasons": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "9"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Saxagliptin 5 mg", "description": "Tablet, Oral, 5 mg, once daily, up to 12 weeks (short-term) and up to 104 weeks (long-term)"}, {"id": "BG001", "title": "Placebo / Metformin", "description": "Placebo Tablet, Oral, 0 mg, once daily, up to 12 weeks; Metformin Tablet, Oral, 500 mg/1000 mg, once daily, starting at Week 12 and up to 104 weeks"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "20"}, {"groupId": "BG001", "value": "16"}, {"groupId": "BG002", "value": "36"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEDIAN", "dispersionType": "FULL_RANGE", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "58", "lowerLimit": "43", "upperLimit": "69"}, {"groupId": "BG001", "value": "55", "lowerLimit": "45", "upperLimit": "69"}, {"groupId": "BG002", "value": "55.5", "lowerLimit": "43", "upperLimit": "69"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "12"}, {"groupId": "BG001", "value": "10"}, {"groupId": "BG002", "value": "22"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "8"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "14"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "White", "categories": [{"measurements": [{"groupId": "BG000", "value": "16"}, {"groupId": "BG001", "value": "12"}, {"groupId": "BG002", "value": "28"}]}]}, {"title": "Black/African American", "categories": [{"measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "7"}]}]}, {"title": "Other", "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "1"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "North America", "categories": [{"measurements": [{"groupId": "BG000", "value": "20"}, {"groupId": "BG001", "value": "16"}, {"groupId": "BG002", "value": "36"}]}]}]}, {"title": "Body Mass Index (BMI)", "paramType": "MEDIAN", "dispersionType": "FULL_RANGE", "unitOfMeasure": "kg/m^2", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "33.36", "lowerLimit": "24.67", "upperLimit": "39.35"}, {"groupId": "BG001", "value": "32.31", "lowerLimit": "25.56", "upperLimit": "38.55"}, {"groupId": "BG002", "value": "33.01", "lowerLimit": "24.67", "upperLimit": "39.35"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Insulin Secretion Rate Area Under the Curve (AUC) During Intravenous (IV)-Oral Hyperglycemic Clamp - Percent Change From Baseline at Week 12", "description": "Adjusted percent change in the insulin secretion rate AUC during a hyperglycemic clamp with an enteral glucose load \\[intravenous-oral hyperglycemic clamp (180-480 minutes)\\] at Week 12. The method used for calculating the insulin secretion rate was C-peptide deconvolution.", "populationDescription": "Randomized participants with both a baseline and post-baseline value (up to Week 12).", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percent Change (Percentage of Baseline)", "timeFrame": "Baseline, Week 12", "groups": [{"id": "OG000", "title": "Short Term Period: Saxagliptin 5 mg", "description": "Tablet, Oral, 5 mg, once daily, up to 12 weeks"}, {"id": "OG001", "title": "Short Term Period: Placebo", "description": "Tablet, Oral, 0 mg, once daily, up to 12 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "15"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "15.9", "lowerLimit": "4.2", "upperLimit": "29.0"}, {"groupId": "OG001", "value": "-2.2", "lowerLimit": "-12.4", "upperLimit": "9.3"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0350", "pValueComment": "Between-group comparisons significant at alpha = 0.05, significance testing based on hierarchical testing. Primary and secondary endpoints are presented in order of testing.", "statisticalMethod": "ANCOVA", "statisticalComment": "Adjusted percent difference for saxagliptin 5 mg vs placebo in Week 12 (LOCF) to baseline ratio. Adjusted for baseline.", "paramType": "Adjusted Percent Difference", "paramValue": "18.5", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.3", "ciUpperLimit": "38.7", "estimateComment": "ANCOVA model: logarithm(post/pre) = logarithm(pre) treatment"}]}, {"type": "SECONDARY", "title": "Insulin Secretion Rate AUC During IV Hyperglycemic Clamp - Percent Change From Baseline at Week 12", "description": "Adjusted percent change in the insulin secretion rate AUC during an intravenous hyperglycemic clamp (120-180 minutes) at Week 12. The method used for calculating the insulin secretion rate was C-peptide deconvolution.", "populationDescription": "Randomized Participants with both a baseline and post-baseline value (up to Week 12).", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percent Change (Percentage of Baseline)", "timeFrame": "Baseline, Week 12", "groups": [{"id": "OG000", "title": "Short Term Period: Saxagliptin 5 mg", "description": "Tablet, Oral, 5 mg, once daily, up to 12 weeks"}, {"id": "OG001", "title": "Short Term Period: Placebo", "description": "Tablet, Oral, 0 mg, once daily, up to 12 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "18"}, {"groupId": "OG001", "value": "16"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "22.6", "lowerLimit": "7.2", "upperLimit": "40.4"}, {"groupId": "OG001", "value": "-4.1", "lowerLimit": "-17.4", "upperLimit": "11.2"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0204", "pValueComment": "Between-group comparisons significant at alpha = 0.05, significance testing based on hierarchical testing. Primary and secondary endpoints are presented in order of testing.", "statisticalMethod": "ANCOVA", "statisticalComment": "Adjusted percent difference for saxagliptin 5 mg vs placebo in Week 12 (LOCF) to baseline ratio. Adjusted for baseline.", "paramType": "Adjusted Percent Difference", "paramValue": "27.9", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "4.2", "ciUpperLimit": "57.1", "estimateComment": "ANCOVA model: logarithm(post/pre) = logarithm(pre) treatment"}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Overall Summary of Adverse Events (AEs) Serious AEs (SAEs), Discontinuations, and Deaths During the ST + LT Treatment Period", "description": "AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event. Related events=relationship of certain, probable, possible, or missing.", "populationDescription": "Treated participants", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "116 weeks", "groups": [{"id": "OG000", "title": "Saxagliptin 5 mg", "description": "Tablet, Oral, 5 mg, once daily, up to 12 weeks (short-term) and up to 104 weeks (long-term)"}, {"id": "OG001", "title": "Placebo / Metformin", "description": "Placebo Tablet, Oral, 0 mg, once daily, up to 12 weeks; Metformin Tablet, Oral, 500 mg/1000 mg, once daily, starting at Week 12 and up to 104 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "20"}, {"groupId": "OG001", "value": "16"}]}], "classes": [{"title": "At Least 1 AE", "categories": [{"measurements": [{"groupId": "OG000", "value": "17"}, {"groupId": "OG001", "value": "14"}]}]}, {"title": "At Least 1 Related AE", "categories": [{"measurements": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "6"}]}]}, {"title": "Deaths", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "At Least 1 SAE", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "2"}]}]}, {"title": "At Least 1 Related SAE", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Discontinuations Due to SAEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "Discontinuations Due to AEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "2"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Marked Laboratory Abnormalities - During ST + LT Treatment Period", "description": "A laboratory value was considered a marked abnormality if it is outside the pre-defined criteria for marked abnormality and the on-treatment value was more extreme (farther from the limit) than the baseline value. Pre-Rx=pretreatment; ULN=upper limit of normal; ALP=alkaline phosphatase; AST=aspartate aminotransferase; ALT=alanine aminotransferase; BUN=blood urea nitrogen; unspec.=unspecified; sodium serum low: \\<0.9 x Pre-Rx \\& \\<=130mEq/L / high: \\>1.1 x Pre-Rx \\& \\>=150mEq/L; potassium, serum low: \\<=0.8 x Pre-Rx \\& \\>=6.0mEq/L / high: 1.2 x Pre-Rx \\& \\>=6.0mEq/L; LLN=lower limit of normal.", "populationDescription": "Number of Participants Analyzed=Treated participants; n=number of treated subjects with baseline value and at least one value during the ST + LT treatment period.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "116 weeks", "groups": [{"id": "OG000", "title": "Saxagliptin 5 mg", "description": "Tablet, Oral, 5 mg, once daily, up to 12 weeks (short-term) and up to 104 weeks (long-term)"}, {"id": "OG001", "title": "Placebo / Metformin", "description": "Placebo Tablet, Oral, 0 mg, once daily, up to 12 weeks; Metformin Tablet, Oral, 500 mg/1000 mg, once daily, starting at Week 12 and up to 104 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "20"}, {"groupId": "OG001", "value": "16"}]}], "classes": [{"title": "Hemoglobin < 8 g/dL (n=0, 0)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Hematocrit < 0.75 x pre-Rx (n=0, 0)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Platelets < 50 x 10^9 c/L (n=0, 0)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Platelets > 1.5 x ULN (n=0, 0)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Leukocytes < 2 x 1000 c/uL (n=0, 0)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Neutrophils+Bands <1x1000 c/uL (n=18, 0)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Eosinophils >0.9x1000 c/uL (n=18, 0)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Lymphocytes <=0.75x1000 c/uL (n=18, 0)", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "ALP >3 x pre-Rx and >ULN (n=0, 0)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "AST >3 x ULN (n=0, 0)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "AST >5 x ULN (n=0, 0)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "ALT >3 x ULN (n=0, 0)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "ALT >5 x ULN (n=0, 0)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Bilirubin Total >2mg/dL (n=0, 0)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "BUN >2 x pre-Rx and >ULN (n=0, 0)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Creatinine >2.5 mg/dL (n=0, 0)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Glucose, Serum Fasting < 50 mg/dL (n=0, 0)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Glucose, Serum Fasting > 500 mg/dL (n=0, 0)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Glucose, Serum Unspec. < 50 mg/dL (n=0, 0)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Glucose, Serum Unspec. > 500 mg/dL (n=0, 0)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Glucose, Plasma Fasting <50 mg/dL (n=0, 0)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Glucose,Plasma Fasting >500 mg/dL (n=0, 0)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Glucose, Plasma Unspec. <50 mg/dL (n=0, 0)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Glucose, Plasma Unspec. >500 mg/dL (n=18, 16)", "categories": [{"measurements": [{"groupId": "OG000", "value": "8"}, {"groupId": "OG001", "value": "9"}]}]}, {"title": "Sodium, Serum Low (see description) (n=0, 0)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Sodium, Serum High (see description) (n=0, 0)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Potassium, Serum Low (see description) (n=0, 0)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Potassium, Serum High (see description) (n=0, 0)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Chloride < 90 mEq/L (n=0, 0)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Chloride > 120 mEq/L (n=0, 0)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Albumin < 0.9 LLN (n=0, 0)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Creatine Kinase > 5 x ULN (n=18, 16)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "Uric Acid > 1.5 x ULN (n=0, 0)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Protein Urine, >=2-4 (n=0, 0)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Blood Urine >=2-4 (n=18, 0)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Red Blood Cells Urine >=2-4 (n=0, 0)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "White Blood Cells Urine >=2-4 (n=0, 0)", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "1"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Short term period (up to 12 weeks) + long term period (up to 104 weeks)", "eventGroups": [{"id": "EG000", "title": "PLACEBO/METFORMIN", "description": "Placebo Tablet, Oral, 0 mg, once daily, up to 12 weeks (short term); Metformin Tablet, Oral, 500 mg titrated to 1000 mg, once daily, up to 104 weeks (long term)", "seriousNumAffected": 2, "seriousNumAtRisk": 16, "otherNumAffected": 14, "otherNumAtRisk": 16}, {"id": "EG001", "title": "SAXAGLIPTIN 5 MG", "description": "Tablet, Oral, 5 mg, once daily, up to 12 weeks (short term); Tablet, Oral, 5 mg, once daily, up to 104 weeks (long term)", "seriousNumAffected": 1, "seriousNumAtRisk": 20, "otherNumAffected": 17, "otherNumAtRisk": 20}], "seriousEvents": [{"term": "ANGINA UNSTABLE", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 20}]}, {"term": "CHOLECYSTITIS", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 20}]}, {"term": "CHEST DISCOMFORT", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 20}]}, {"term": "COLON CANCER", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 20}]}], "otherEvents": [{"term": "EYE IRRITATION", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 20}]}, {"term": "LACRIMATION INCREASED", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 20}]}, {"term": "CARDIAC MURMUR", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 20}]}, {"term": "URINE OUTPUT DECREASED", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 20}]}, {"term": "BLOOD PRESSURE INCREASED", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 20}]}, {"term": "EOSINOPHIL COUNT INCREASED", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 20}]}, {"term": "LYMPHOCYTE COUNT DECREASED", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 20}]}, {"term": "NEUTROPHIL COUNT DECREASED", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 20}]}, {"term": "BLOOD CREATINE PHOSPHOKINASE INCREASED", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 20}]}, {"term": "TACHYCARDIA", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 20}]}, {"term": "HAEMATOMA", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 20}]}, {"term": "HOT FLUSH", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 20}]}, {"term": "HYPERTENSION", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 20}]}, {"term": "PERIPHERAL COLDNESS", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 20}]}, {"term": "STRESS", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 20}]}, {"term": "INSOMNIA", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 20}]}, {"term": "AGITATION", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 20}]}, {"term": "HYPERSENSITIVITY", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 20}]}, {"term": "SEASONAL ALLERGY", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 20}]}, {"term": "TREMOR", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 20}]}, {"term": "AGEUSIA", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 20}]}, {"term": "HEADACHE", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 20}]}, {"term": "DIZZINESS", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 20}]}, {"term": "DYSGEUSIA", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 20}]}, {"term": "PRESYNCOPE", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 20}]}, {"term": "PARAESTHESIA", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 20}]}, {"term": "HYPOAESTHESIA", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 20}]}, {"term": "SINUS HEADACHE", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 20}]}, {"term": "NEUROPATHY PERIPHERAL", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 20}]}, {"term": "CARPAL TUNNEL SYNDROME", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 20}]}, {"term": "NAUSEA", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 20}]}, {"term": "VOMITING", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 20}]}, {"term": "DIARRHOEA", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 20}]}, {"term": "DYSPEPSIA", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 20}]}, {"term": "GASTRITIS", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 20}]}, {"term": "FLATULENCE", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 20}]}, {"term": "GASTRIC ULCER", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 20}]}, {"term": "ABDOMINAL PAIN", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 20}]}, {"term": "FAECES DISCOLOURED", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 20}]}, {"term": "ABDOMINAL DISCOMFORT", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 20}]}, {"term": "ABDOMINAL PAIN UPPER", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 20}]}, {"term": "GASTROOESOPHAGEAL REFLUX DISEASE", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 20}]}, {"term": "VERTIGO", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 20}]}, {"term": "MIDDLE EAR EFFUSION", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 20}]}, {"term": "CYSTITIS", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 20}]}, {"term": "RHINITIS", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 20}]}, {"term": "INFLUENZA", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 20}]}, {"term": "SINUSITIS", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 20}]}, {"term": "BRONCHITIS", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 20}]}, {"term": "BACTERIURIA", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 20}]}, {"term": "INFECTED CYST", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 20}]}, {"term": "LABYRINTHITIS", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 20}]}, {"term": "TOOTH ABSCESS", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 20}]}, {"term": "OTITIS EXTERNA", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 20}]}, {"term": "GASTROENTERITIS", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 20}]}, {"term": "NASOPHARYNGITIS", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 20}]}, {"term": "KIDNEY INFECTION", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 20}]}, {"term": "GASTROENTERITIS VIRAL", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 20}]}, {"term": "HELICOBACTER INFECTION", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 20}]}, {"term": "URINARY TRACT INFECTION", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 20}]}, {"term": "RESPIRATORY TRACT INFECTION", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 20}]}, {"term": "VULVOVAGINAL MYCOTIC INFECTION", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 20}]}, {"term": "UPPER RESPIRATORY TRACT INFECTION", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 20}]}, {"term": "VIRAL UPPER RESPIRATORY TRACT INFECTION", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 20}]}, {"term": "BLADDER DILATATION", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 20}]}, {"term": "HYPERLIPIDAEMIA", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 20}]}, {"term": "ANAEMIA", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 20}]}, {"term": "LYMPHOPENIA", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 20}]}, {"term": "RASH", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 20}]}, {"term": "ERYTHEMA", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 20}]}, {"term": "URTICARIA", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 20}]}, {"term": "SKIN LESION", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 20}]}, {"term": "RASH GENERALISED", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 20}]}, {"term": "PROSTATITIS", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 20}]}, {"term": "GYNAECOMASTIA", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 20}]}, {"term": "TESTICULAR PAIN", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 20}]}, {"term": "UTERINE PROLAPSE", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 20}]}, {"term": "ENDOMETRIAL HYPERTROPHY", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 20}]}, {"term": "PROSTATIC CALCIFICATION", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 20}]}, {"term": "BENIGN PROSTATIC HYPERPLASIA", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 20}]}, {"term": "LIMB INJURY", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 20}]}, {"term": "MUSCLE STRAIN", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 20}]}, {"term": "ANKLE FRACTURE", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 20}]}, {"term": "HEAT EXHAUSTION", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 20}]}, {"term": "PROCEDURAL PAIN", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 20}]}, {"term": "ROAD TRAFFIC ACCIDENT", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 20}]}, {"term": "POST PROCEDURAL SWELLING", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 20}]}, {"term": "MYALGIA", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 20}]}, {"term": "BACK PAIN", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 20}]}, {"term": "NECK PAIN", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 20}]}, {"term": "ARTHRALGIA", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 20}]}, {"term": "TENDONITIS", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 20}]}, {"term": "MUSCLE SPASMS", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 20}]}, {"term": "JOINT SWELLING", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 20}]}, {"term": "PAIN IN EXTREMITY", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 20}]}, {"term": "MUSCULOSKELETAL PAIN", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 20}]}, {"term": "COUGH", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 20}]}, {"term": "ASTHMA", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 20}]}, {"term": "SINUS CONGESTION", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 20}]}, {"term": "OROPHARYNGEAL PAIN", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 20}]}, {"term": "SLEEP APNOEA SYNDROME", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 20}]}, {"term": "PAIN", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 20}]}, {"term": "FATIGUE", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 20}]}, {"term": "CHEST PAIN", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 20}]}, {"term": "HERNIA PAIN", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 20}]}, {"term": "CHEST DISCOMFORT", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 20}]}, {"term": "OEDEMA PERIPHERAL", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 20}]}, {"term": "INFUSION SITE PAIN", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 20}]}, {"term": "INFUSION SITE DISCOMFORT", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 20}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period \u226460 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication."}, "pointOfContact": {"title": "Boaz Hirschberg", "organization": "AstraZeneca Pharmaceuticals", "email": "ClinicalTrialTransparency@astrazeneca.com"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "relevance": "LOW"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Type 2 Diabetes", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "C000502994", "term": "Saxagliptin"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000054795", "term": "Incretins"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000054873", "term": "Dipeptidyl-Peptidase IV Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M228152", "name": "Saxagliptin", "asFound": "Manufacturer", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M27905", "name": "Incretins", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M27957", "name": "Dipeptidyl-Peptidase IV Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}